<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005107</url>
  </required_header>
  <id_info>
    <org_study_id>KSteffenVLX</org_study_id>
    <secondary_id>EPSCOR</secondary_id>
    <nct_id>NCT02005107</nct_id>
  </id_info>
  <brief_title>Venlafaxine PK Following Bariatric Surgery</brief_title>
  <acronym>VLX</acronym>
  <official_title>A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Dakota State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neuropsychiatric Research Institute, Fargo, North Dakota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Dakota State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate how the body absorbs and processes the immediate&#xD;
      release (IR) and sustained release (XR) medication venlafaxine (EffexorÂ®). Subject who are&#xD;
      1-3 years post gastric bypass or sleeve gastrectomy surgery will be invited to participate.&#xD;
      Non-surgical controls will also be enrolled based on a matching criteria to post gastric&#xD;
      bypass subjects. Participants will be asked to complete two 12-hour study days approximately&#xD;
      11 days apart. This study will enroll up to 30 participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC)</measure>
    <time_frame>24 hours intervals</time_frame>
    <description>The primary aim of this research is to provide a comparison of pharmacokinetic measures associated with a single dose of venlafaxine IR (immediate release) and venlafaxine XR (sustained release) in Roux-en-Y Gastric Bypass, Sleeve Gastrectomy, and matched nonsurgical &quot;control&quot; subjects. Comparisons will be based upon venlafaxine plasma concentrations obtained during the 24 hour sample collection window.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK Characteristics (Composite)</measure>
    <time_frame>24 hour collection</time_frame>
    <description>We will also evaluate other PK characteristics associated with venlafaxine, such as Cmax, Tmax, t1/2, and the ratio of venlafaxine to the active metabolite ODV, and others.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Roux en Y Gastric Bypass</condition>
  <condition>Sleeve Gastrectomy</condition>
  <arm_group>
    <arm_group_label>venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venlafaxine IR and XR, single dosages of each separated by a wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine XR and Venlafaxine IR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine IR and Venlafaxine XR</intervention_name>
    <arm_group_label>Venlafaxine XR and Venlafaxine IR</arm_group_label>
    <arm_group_label>venlafaxine</arm_group_label>
    <other_name>Effexor and Effexor XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Age 18-65 (inclusive, at time of informed consent)&#xD;
&#xD;
          3. No tobacco use in the past three months.&#xD;
&#xD;
          4. Underwent Roux-en-Y Gastric Bypass or Sleeve Gastrectomy weight loss surgery 12-36&#xD;
             months prior to study OR has not had a weight loss surgery but matches the gastric&#xD;
             bypass patients on age, gender, and BMI. Criteria for matching will be established at&#xD;
             the beginning of the study in consultation with the statistical team and addressed as&#xD;
             needed with the input of the biostatistician.&#xD;
&#xD;
          5. Ability to read, write and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Taking a medication that has a clinically significant interaction with venlafaxine or&#xD;
             an interaction that may alter the study data.&#xD;
&#xD;
          2. Hypersensitivity to venlafaxine or any excipient contained within the dosage forms&#xD;
&#xD;
          3. Inability to tolerate repeated blood draws.&#xD;
&#xD;
          4. Any history of bipoloar disorder or a psychotic disorder.&#xD;
&#xD;
          5. Current major depressive disorder or current suicidality.&#xD;
&#xD;
          6. Alcohol or substance dependence in the past year.&#xD;
&#xD;
          7. Currently pregnant or lactating or unwillingness to use medically accepted&#xD;
             contraception during study&#xD;
&#xD;
          8. Taking a medication which significantly alters gastrointesinal transit time or&#xD;
             significantly reduces acid secretion (e.g. routine use of proton pump inhibitors, H2&#xD;
             antagonists, sucralfate).&#xD;
&#xD;
          9. Medical conditon which may increase participant risk with venlafaxine or uncontrolled&#xD;
             hypertension at the discretion of the examining provider.&#xD;
&#xD;
         10. Hepatic insufficiency as defined by any hepatic enzyme greater than 3x the upper limit&#xD;
             of normal or other hepatic laboratory abnormalities at the discretion of the medical&#xD;
             provider.&#xD;
&#xD;
         11. Renal impairment as evidence by a calculated creatinine clearance of less than or&#xD;
             equal to 70ml/min or other abnormality on a renal panel that the medical provider&#xD;
             feels puts the participant at risk.&#xD;
&#xD;
         12. Poor or ultra-rapid Cytochrome P450 2D6 metabolizer.&#xD;
&#xD;
         13. Self reported history of viral hepatits or HIV.&#xD;
&#xD;
         14. Positive urine drug screen unless documented prescription of a non-interacting&#xD;
             medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine J Steffen, Pharm.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Dakota State University &amp; Neuropsychiatric Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuropsychiatric Research Institute</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nrifargo.com</url>
    <description>Neuropsychiatric Research Institute Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Dakota State University</investigator_affiliation>
    <investigator_full_name>Kristine Steffen</investigator_full_name>
    <investigator_title>Associate Professor, North Dakota State University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

